Handelsbanken Fonder AB Acquires 138,430 Shares of Halozyme Therapeutics, Inc. $HALO

Posted by Francis Steltz on Aug 12th, 2026

Handelsbanken Fonder AB grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 28.1% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 631,899 shares of the biopharmaceutical company’s stock after purchasing an additional 138,430 shares during the quarter. Handelsbanken Fonder AB’s holdings in Halozyme Therapeutics were worth $49,459,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Measured Wealth Private Client Group LLC grew its stake in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares in the last quarter. Larson Financial Group LLC increased its holdings in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the last quarter. Harbour Investments Inc. lifted its stake in Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares in the last quarter. Clearstead Advisors LLC lifted its stake in Halozyme Therapeutics by 64.8% in the 4th quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 331 shares in the last quarter. Finally, Wexford Capital LP bought a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at about $70,000. Institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of several research reports. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Morgan Stanley dropped their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. TD Cowen lifted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, HC Wainwright increased their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $91.20.

View Our Latest Stock Report on HALO

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at $51,886,572.40. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 44,103 shares of company stock worth $3,142,896 over the last quarter. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $102.62 on Wednesday. The firm has a market capitalization of $11.65 billion, a price-to-earnings ratio of 30.63, a PEG ratio of 0.43 and a beta of 0.85. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The business has a 50 day simple moving average of $77.89 and a 200-day simple moving average of $71.92. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $104.78.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the previous year, the company posted $1.54 EPS. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.